Matthew K. Fust, Director: Neumora Therapeutics NMRA Sell · Filed 24/10/18

Trade details

Type: Insider sale
Amount: $239,254.47
Shares · price: 14,049 sh · $17.03 a share
Held after: 20,100 sh
Stock: Neumora Therapeutics NMRA
Person: Matthew K. FustDirector
Trade date: 24/10/18
Filed: 24/10/18
Days to filing: 0 days

Sold 41.1% of holdings

Share of holding sold: 41.1%

Neumora Therapeutics trades, last 26 weeks

What else happened in Neumora Therapeutics around then

Filed or reported within 30 days of the trade day · 24/09/18~24/11/17

Matthew K. Fust's recent trades

Matthew K. FustDirector
Sell10b5-1 planCrinetics Pharmaceuticals
Sell10b5-1 plan
Crinetics Pharmaceuticals
CRNX
$716K
16,000 sh
$716K
Filed 25/09/30
Traded 25/09/26
Matthew K. FustDirector
Sell10b5-1 planNeumora Therapeutics
Sell10b5-1 plan
Neumora Therapeutics
NMRA
$131.6K
7,739 sh
$131.6K
Filed 24/10/18
Traded 24/10/17
Matthew K. FustDirector
Sell10b5-1 planCrinetics Pharmaceuticals
Sell10b5-1 plan
Crinetics Pharmaceuticals
CRNX
$796.3K
17,500 sh
$796.3K
Filed 24/03/22
Traded 24/03/20
Matthew K. FustDirector
Sell10b5-1 planCrinetics Pharmaceuticals
Sell10b5-1 plan
Crinetics Pharmaceuticals
CRNX
$762.7K
17,500 sh
$762.7K
Filed 24/03/22
Traded 24/03/20
Matthew K. FustDirector
Sell10b5-1 planCrinetics Pharmaceuticals
Sell10b5-1 plan
Crinetics Pharmaceuticals
CRNX
$544.6K
12,500 sh
$544.6K
Filed 24/03/22
Traded 24/03/20